Scholarlink

Background <p>Large type 3 (≥ 8&#xa0;cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors.</p> Methods <p>Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40&#xa0;mg/m<sup>2</sup>, oxaliplatin 100&#xa0;mg/m<sup>2</sup>, and oral S-1 at 80&#xa0;mg/m<sup>2</sup>/day for 14&#xa0;days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3&#xa0;year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10.</p> Results <p>Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1–50.6%; 80% CI 28.6–46.4%; <i>p</i> = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2–65.0%).</p> Conclusions <p>Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)

  • 期刊论文

  • 发表日期：

    2026年1月21日

查看全文
  • Shunji Endo,
  • Ryo Tanaka,
  • Toshifumi Yamaguchi,
  • Hiromichi Miyagaki,
  • Junji Kawada,
  • Takeshi Omori,
  • Naoki Takahashi,
  • Toru Masuzawa,
  • Haruna Furukawa,
  • Yuya Sato,
  • Atsushi Takeno,
  • Naoki Shinno,
  • Ryohei Kawabata,
  • Shinsuke Katsuyama,
  • Shigeyoshi Higashi,
  • Yukinori Kurokawa,
  • Toshimasa Tsujinaka,
  • Toshio Shimokawa,
  • Taroh Satoh

摘要

Background

Large type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors.

Methods

Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m2, oxaliplatin 100 mg/m2, and oral S-1 at 80 mg/m2/day for 14 days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3 year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10.

Results

Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1–50.6%; 80% CI 28.6–46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2–65.0%).

Conclusions

Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.